REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot85910.21518/1561-5936-2021-2-62-68Original ArticleA current approach to the treatment of ulcerative colitis: updated recommendations of the American Gastroenterological AssociationVodovozovAlexey-Remedium141220212626817032022Copyright © 2021,2021Ulcerative colitis (UC) is a chronic inflammatory bowel disease that generally begins in young adulthood [1]. If left untreated, it can present with recurrent inflammations of the mucous membrane. Findings from population cohort studies show that UC follows a mild or moderate clinical course in most cases, the most active phase of the disease usually coincides in time with establishing diagnosis, followed by remission and exacerbation periods of varying length and intensity. Approximately 15% of patients may have an aggressive course of the disease, and 20% of such patients may require hospitalization due to the severity of the condition [2].ulcerative colitismoderate degreesevere degreeofficial recommendations of the American Gastroenterological Associationvedolizumabязвенный колитсредняя степеньтяжелая степеньофициальные рекомендации Американской гастроэнтерологической ассоциацииведолизумаб1.Fumery M., Singh S., Dulai P.S., Gower-Rousseau C., PeyrinBiroulet L., Sandborn W.J. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16(3):343–356.e3. https://doi.org/10.1016/j.cgh.2017.06.016.2.Narula N., Marshall J.K., Colombel J.F. et al. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111(4):477–491. https://doi.org/10.1038/ajg.2016.7.3.Dassopoulos T., Cohen R.D., Scherl E.J., Schwartz R.M., Kosinski L., Regueiro M.D. Ulcerative Colitis Care Pathway. Gastroenterology. 2015;149(1):238–245. https://doi.org/10.1053/j.gastro.2015.05.036.4.Feuerstein J.D., Isaacs K.L., Schneider Y., Siddique S.M., FalckYtter Y., Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450–1461. https://doi.org/10.1053/j.gastro.2020.01.006.5.Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629. https://doi.org/10.1056/NEJM198712243172603.6.Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–1048. https://doi.org/10.1136/bmj.2.4947.1041.7.Singh S., Murad M.H., Fumery M., Dulai P.S., Sandborn W.J. Firstand second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network metaanalysis. Clin Gastroenterol Hepatol. 2020. https://doi.org/10.1016/j.cgh.2020.01.008.8.Cipriani A., Higgins J.P., Geddes J.R., Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130–137. https://doi.org/10.7326/0003-4819-159-2-201307160-00008.9.Caprilli R., Carratù R., Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis. 1975;20(2):115–120. https://doi.org/10.1007/BF01072336.10.Jewell D.P., Truelove S.C. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974;4(5945):627–630. https://doi.org/10.1136/bmj.4.5945.627.11.Maté-Jiménez J., Hermida C., Cantero-Perona J., Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12(11):1227–1233. https://doi.org/10.1097/00042737-200012110-00010.12.Rosenberg J.L., Wall A.J., levin B., Binder H.J., Kirsner J.B. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology. 1975;69(1):96–99. Available at: https://pubmed.ncbi.nlm.nih.gov/1097295.13.Sood A., Midha V., Sood N., Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000;19(1):14–16. Available at: https://pubmed.ncbi.nlm.nih.gov/10659481.14.Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47–53. https://doi.org/10.1136/gut.2005.068809.15.Hawthorne A.B., logan R.F., Hawkey C.J. et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305(6844):20–22. https://doi.org/10.1136/bmj.305.6844.20.16.Sood A., Kaushal V., Midha V., Bhatia K.L., Sood N., Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002;37(4):270–274. https://doi.org/10.1007/s005350200034.17.Sood A., Midha V., Sood N., Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003;22(3):79–81. Available at: https://pubmed.ncbi.nlm.nih.gov/12839376.18.Herfarth H., Barnes E.L., Valentine J.F. et al. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology. 2018;155(4):1098–1108.e9. https://doi.org/10.1053/j.gastro.2018.06.046.19.Oren R., Arber N., Odes S. et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996;110(5):1416–1421. https://doi.org/10.1053/gast.1996.v110.pm8613046.20.Panaccione R., Ghosh S., Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3. https://doi.org/10.1053/j.gastro.2013.10.052.21.Vermeire S., Gils A., Accossato P., lula S., Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. https://doi.org/10.1177/1756283X17750355.22.Torres J., Bonovas S., Doherty G. et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4–22. https://doi.org/10.1093/ecco-jcc/jjz180.